Brickell Biotech, Inc. (“Brickell”), a clinical-stage pharmaceutical company focused on the development of differentiated, innovative therapeutics to satisfy current unmet human needs in the global dermatology markets, today announced the outcome of a pilot study of a new compound, BBI-4000, for the topical treatment of primary axillary hyperhidrosis, or excessive sweating.
Shoe Sensation is taking rural communities by storm as it opens its 100th store this year and celebrates 30 years of bringing well-known footwear brands to small-town America. "We have been able to survive through the thick and thin of the economy and expand our model currently to 14 states – 16 states come September," CEO Mike Zawoysky says. “We have been able to deliver new stores each year and comparable store growth for each of the past six consecutive years."
Telerx, a leader in U.S. customer care services, today announced that it has completed its acquisition of C3i, a leading provider of technology support services for the life sciences industry. This acquisition will provide Telerx with the global infrastructure to expand its business services outside the United States while maintaining its current domestic operations. The acquisition was completed on June 30, 2014.
Brickell Biotech, Inc. ("Brickell"), a clinical-stage pharmaceutical company focused on the development of differentiated, innovative, therapeutics to satisfy current unmet human needs in the global dermatology markets, today announced that it has entered into a license agreement with Merz North America, Inc. ("Merz"). The agreement grants Merz an exclusive North American license, with certain additional international rights, to develop and commercialize a completely novel retinoid compound, BBI-3000, for the treatment of skin conditions known to be responsive to retinoid agents, such as acne and psoriasis.
GE Healthcare Life Sciences (NYSE: GE) and Promosome LLC announced today that the companies have signed a licensing agreement, granting GE Healthcare exclusive rights to an innovative suite of mammalian cell line development technologies, developed by Promosome, for increasing protein expression in mammalian cell culture. Under the terms of agreement, Promosome will receive milestone payments for technology transfer and subsequent royalties upon commercialization.
Send Word Now, leading worldwide provider of enterprise-class critical communications, has again been named as a ‘Leader’ in Gartner Inc.’s Magic Quadrant for U.S. Emergency/Mass Notification Services (EMNS).
‘Leaders,’ as defined by Gartner, "have products that work well for Gartner clients in midsize and large deployments. They excel in the combination of market understanding, product features and functions, and overall viability as a firm. Their EMNS products are well-known to clients, and are frequently found on RFP shortlists."
In January 2021, Palisade Capital Management published a research piece entitled “The Time For Convertibles Is (Still) Now”, where we outlined the advantages of investing in the convertible asset class, both historically and tactically, given an impending, post COVID-19 economic cycle.
In this study, we seek to touch upon and update key aspects of Palisade's unique approach to investing in convertibles. Palisade's convertible strategies emphasize Growth convertibles (as opposed to Value convertibles) and Large- and Mid-Capitalization convertibles (rather than Small-Capitalization convertibles).